Case Report: FIA plus venetoclax in a patient on hemodialysis
The safe and effective delivery of curative cytotoxic chemotherapy for acute myeloid leukemia (AML) in patients receiving intermittent hemodialysis (IHD) for end-stage renal disease (ESRD) remains a clinical challenge; pharmacological and logistical barriers necessitate close interdisciplinary coordination. In this case, we report a 65-year-old female patient with chronic ESRD on IHD and newly diagnosed AML who achieved complete remission (CR) after treatment with fludarabine, idarubicin, and cytarabine plus venetoclax (i.e., FIA + venetoclax).
Authors
- Kayleigh Marx (ORCID: https://orcid.org/0000-0001-9468-9707)
- Musa Yılmaz (ORCID: https://orcid.org/0000-0002-4498-4895)
- T. M. Kadia
- Nicholas J. Short
- Courtney D. DiNardo
- Wei Ying Jen (ORCID: https://orcid.org/0000-0002-9339-3362)
- Farhad Ravandi
- Naval G. Daver
- Jacob E. Herstein
- Ghayas C. Issa
- J. Michael Savoy
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- The University of Texas Health Science Center at Houston (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-01-15
- DOI
- https://doi.org/10.3389/fonc.2025.1740357
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00